Topics

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 17, Status: Authorised

07:40 EDT 5 Jul 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 17, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 17, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Benlysta, belimumab, Lupus Erythematosus, Systemic, Date of authorisation: 13/07/2011, Revision: 17, Status: Authorised"

Quick Search

Relevant Topic

Lupus
Lupus is a complex and poorly understood condition that affects many parts of the body and causes symptoms ranging from mild to life-threatening. There are several types of lupus. The main types are: discoid lupus erythematosus drug-induced lu...